Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asth...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Allergy Asthma Clin Immunol
Hlavní autoři: Mukherjee, Manali, Lim, Hui Fang, Thomas, Sruthi, Miller, Douglas, Kjarsgaard, Melanie, Tan, Bruce, Sehmi, Roma, Khalidi, Nader, Nair, Parameswaran
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216532/
https://ncbi.nlm.nih.gov/pubmed/28070196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-016-0174-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky